High levels of platelet-lymphocyte complexes in psoriasis patients are associated with a better response to anti-TNF-α therapy.
Psoriasis is currently considered to be an immune-mediated disease whose patho-mechanisms involve platelet activation, which seems to correlate with activity disease. Platelet activation is associated with the formation of platelet-lymphocyte complexes, though their significance remains unknown. Moreover, biological treatments targeting TNF-α reduce platelet activation.